Jonathan Staffeldt has served as General Counsel of the Company since April 2024 and previously as Deputy General Counsel since January 2023. He also serves as Corporate Secretary.
Prior to that, Mr. Staffeldt was Chief Legal Officer of GVB Biopharma, the former subsidiary of the Company that was acquired in May 2022, from September 2019. He was previously in private practice with significant experience in corporate, mergers and acquisitions, and litigation. He received his B.S. in Accounting from the University of Southern California and his Juris Doctorate from the University of California Los Angeles.
Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.